Stratos Wealth Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.95M | Buy |
15,684
+225
| +1% | +$48.4K | 0.22% | 105 |
|
|
2026
Q1 | $3.36M | Sell |
15,459
-445
| -3% | -$98.7K | 0.21% | 105 |
|
|
2025
Q4 | $3.63M | Buy |
15,904
+38
| +0.2% | +$8.66K | 0.18% | 129 |
|
|
2025
Q3 | $3.67M | Buy |
15,866
+1,073
| +7% | +$219K | 0.18% | 130 |
|
|
2025
Q2 | $2.75M | Sell |
14,793
-69
| -0.5% | -$12.8K | 0.14% | 145 |
|
|
2025
Q1 | $3.11M | Sell |
14,862
-9,297
| -38% | -$1.81M | 0.17% | 125 |
|
|
2024
Q4 | $4.29M | Buy |
24,159
+58
| +0.2% | +$10.7K | 0.21% | 112 |
|
|
2024
Q3 | $4.76M | Buy |
24,101
+18
| +0.1% | +$3.36K | 0.22% | 102 |
|
|
2024
Q2 | $4.13M | Sell |
24,083
-516
| -2% | -$85.5K | 0.2% | 112 |
|
|
2024
Q1 | $4.48M | Sell |
24,599
-34,752
| -59% | -$5.99M | 0.27% | 91 |
|
|
2023
Q4 | $9.2M | Sell |
59,351
-2,877
| -5% | -$419K | 0.53% | 30 |
|
|
2023
Q3 | $9.28M | Buy |
62,228
+10,205
| +20% | +$1.5M | 0.61% | 26 |
|
|
2023
Q2 | $7.01M | Sell |
52,023
-227
| -0.4% | -$33.3K | 0.5% | 38 |
|
|
2023
Q1 | $8.33M | Sell |
52,250
-695
| -1% | -$106K | 0.64% | 23 |
|
|
2022
Q4 | $8.56M | Buy |
52,945
+1,953
| +4% | +$299K | 0.71% | 22 |
|
|
2022
Q3 | $6.84M | Sell |
50,992
-4,191
| -8% | -$601K | 0.72% | 23 |
|
|
2022
Q2 | $8.45M | Buy |
55,183
+229
| +0.4% | +$35K | 0.77% | 18 |
|
|
2022
Q1 | $8.91M | Sell |
54,954
-3,400
| -6% | -$494K | 0.72% | 22 |
|
|
2021
Q4 | $7.9M | Buy |
58,354
+742
| +1% | +$87.6K | 0.57% | 35 |
|
|
2021
Q3 | $6.21M | Sell |
57,612
-488
| -0.8% | -$55.8K | 0.53% | 38 |
|
|
2021
Q2 | $6.54M | Buy |
58,100
+2,643
| +5% | +$298K | 0.58% | 30 |
|
|
2021
Q1 | $6M | Sell |
55,457
-3,462
| -6% | -$370K | 0.64% | 28 |
|
|
2020
Q4 | $6.31M | Buy |
58,919
+6,065
| +11% | +$583K | 0.87% | 18 |
|
|
2020
Q3 | $4.63M | Buy |
52,854
+426
| +0.8% | +$40.1K | 1.13% | 20 |
|
|
2020
Q2 | $5.15M | Buy |
52,428
+42,460
| +426% | +$3.74M | 1.58% | 11 |
|
|
2020
Q1 | $759K | Buy |
9,968
+529
| +6% | +$45.1K | 0.54% | 52 |
|
|
2019
Q4 | $836K | Sell |
9,439
-2,040
| -18% | -$169K | 0.47% | 52 |
|
|
2019
Q3 | $869K | Buy |
11,479
+233
| +2% | +$16K | 0.33% | 79 |
|
|
2019
Q2 | $818K | Buy |
11,246
+227
| +2% | +$17.8K | 0.33% | 74 |
|
|
2019
Q1 | $888K | Buy |
11,019
+26
| +0.2% | +$2.13K | 0.48% | 54 |
|
|
2018
Q4 | $1.01M | Buy |
+10,993
| New | +$967K | 0.68% | 35 |
|
Other funds holding ABBV
Stratos Wealth Advisors's ABBV Position: Q2 2026 in Review
Stratos Wealth Advisors increased its AbbVie (ABBV) stake by 1.5% in Q2 2026, buying an estimated $48.4K and bringing the position to 15,684 shares worth $3.95M. The position accounts for 0.22% of the portfolio, ranked #105.
Stratos Wealth Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $9.28M in Q3 2023. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Stratos Wealth Advisors held 15,684 shares of AbbVie worth $3.95M as of Q2 2026.
- Stratos Wealth Advisors bought 225 AbbVie shares in Q2 2026, an estimated $48.4K.
- AbbVie made up 0.22% of Stratos Wealth Advisors's portfolio in Q2 2026, its #105 holding.
- Stratos Wealth Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- Stratos Wealth Advisors's AbbVie position peaked at $9.28M in Q3 2023.
- 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.